FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.
What happened
FDA inspected Huons' drug manufacturing facility in Jecheon, South Korea, from November 12 to 21, 2025. Investigators found manipulated and discarded microbiology test data, blank uncontrolled forms, fabricated logbook pages, inadequate investigations of failed test results, and poor airflow and glove controls on aseptic filling lines. The company suspended U.S. drug production and committed to a voluntary recall of all drugs made at the facility for the U.S. market.
What FDA found
Laboratory records did not include complete original data; staff discarded bioburden plates with growth, manipulated camera timestamps, removed and fabricated logbook pages, and left an endotoxin failure undocumented.
21 CFR 211.194(a)The company did not thoroughly investigate failed test results and used a passing retest to invalidate an original failure.
21 CFR 211.192Smoke studies showed turbulent airflow and operators blocking first air in ISO 5 aseptic filling areas.
21 CFR 211.113(b)Procedures for monitoring and cleaning gloves used in aseptic filling were inadequate and did not ensure all gloves were tested or frequently disinfected.
21 CFR 211.42(c)(10)(vi)The quality unit lacked effective oversight and authority over laboratory and production operations.
21 CFR 211.22
What FDA wants
FDA asks Huons to provide a comprehensive data integrity investigation and corrective action plan, an independent retrospective review of invalidated failed test results, contamination-hazard and environmental-monitoring assessments, and remediation timelines. It also asks the company to clarify whether it intends to resume U.S. drug manufacturing and to notify FDA before resuming; the letter does not state a response deadline.
Who should pay attention
- U.S. buyers and distributors of Huons-made drugs
- companies relying on microbiology or sterility data from contract manufacturers
- sterile drug manufacturers and their quality units
This is a summary. Read the original letter on fda.gov.